Advertisement

 

 

Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.

Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
Author Information (click to view)

Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Van Vuuren C, Macleod W, Sanne I, Stevens WS, Carmona SC,


Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Van Vuuren C, Macleod W, Sanne I, Stevens WS, Carmona SC, (click to view)

Steegen K, Bronze M, Papathanasopoulos MA, van Zyl G, Goedhals D, Van Vuuren C, Macleod W, Sanne I, Stevens WS, Carmona SC,

Advertisement

The Journal of infectious diseases 2016 10 20214(12) 1826-1830

Abstract

Limited data exist on human immunodeficiency virus type 1 (HIV-1) resistance in patients who are not responding to protease inhibitor (PI)-based regimens in resource-limited settings. This study assessed resistance profiles in adults across South Africa who were not responding to PI-based regimens. pol sequencing was undertaken and submitted to the Stanford HIV Drug Resistance Database. At least 1 major PI mutation was detected in 16.4% of 350 participants. A total of 53.4% showed intermediate resistance to darunavir/ritonavir, whereas high-level resistance was not observed. Only 5.2% and 32.8% of participants showed high-level and intermediate resistance to etravirine, respectively. Although the prevalence of major PI mutations was within previously reported ranges, most patients will likely experience virological suppression during receipt of currently available South African third-line regimens.

Submit a Comment

Your email address will not be published. Required fields are marked *

17 + sixteen =

[ HIDE/SHOW ]